Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Amarjeet, Tank"'
Autor:
Yongjun Wang, S Claiborne Johnston, Pierre Amarenco, Carl Mellström, Mario Ouwens, Scott R Evans, Ritika Jain, Stefan James, Hans Denison, Per Ladenvall, Carlos A Molina, Anders Himmelmann, Mikael Knutsson, Amarjeet Tank, Klas Rikner
Publikováno v:
BMJ Neurology Open, Vol 5, Iss 2 (2023)
Objective THALES demonstrated that ticagrelor plus aspirin reduced the risk of stroke or death but increased bleeding versus aspirin during the 30 days following a mild-to-moderate acute non-cardioembolic ischaemic stroke (AIS) or high-risk transient
Externí odkaz:
https://doaj.org/article/ca42b3bf4bfc4422864b26bffd2bd5bc
Autor:
Philippe Gabriel Steg, Deepak L Bhatt, Stefan K James, Oliver Darlington, Louise Hoskin, Tabassome Simon, Kim M Fox, Lawrence A Leiter, Shamir R Mehta, Robert A Harrington, Anders Himmelmann, Wilhelm Ridderstråle, Marielle Andersson, Héctor Bueno, Leonardo De Luca, Amarjeet Tank, Carl Mellström, Phil McEwan
Publikováno v:
European Heart Journal - Cardiovascular Pharmacotherapy. 8:777-785
Aims To conduct a health economic evaluation of ticagrelor in patients with type 2 diabetes and coronary artery disease (CAD) from a multinational payer perspective. Cost–effectiveness and cost–utility of ticagrelor were evaluated in the overall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::821176274e3b416ddc33a356e212a23f
https://doi.org/10.1093/ehjcvp/pvac032
https://doi.org/10.1093/ehjcvp/pvac032
Autor:
Jason Gordon, Amarjeet Tank, Hayley Bennet, Lee Beresford-Hulme, Phil McEwan, Markus F. Scheerer, Thomas Danne, Christopher Edmonds, Fredrik Thoren
Publikováno v:
Diabetes Therapy
Introduction Dapagliflozin is an orally active inhibitor of sodium-glucose co-transporter 2 (SGLT2) that is indicated for use in adults with type 1 diabetes (T1DM) (with a body mass index (BMI) of at least 27 kg/m2 in Europe, no such BMI limit in Jap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c497fa6104ace37b10d6a8d383c672
http://europepmc.org/articles/PMC7192983
http://europepmc.org/articles/PMC7192983
Publikováno v:
Diabetes, Obesity and Metabolism. 22:1047-1055
Aims To assess the cost-effectiveness of dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, as an adjunct to insulin in adults with type 1 diabetes mellitus (T1DM) inadequately controlled by insulin alone in the UK setting. Methods A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb57caff6428517bdaf90caadff9a133
https://doi.org/10.1111/dom.13992
https://doi.org/10.1111/dom.13992
Autor:
Keon-Joo, Lee, Dong Woo, Shin, Hong-Kyun, Park, Beom Joon, Kim, Jong-Moo, Park, Kyusik, Kang, Tai Hwan, Park, Kyung Bok, Lee, Keun-Sik, Hong, Yong-Jin, Cho, Dong-Eog, Kim, Wi-Sun, Ryu, Byung-Chul, Lee, Kyung-Ho, Yu, Mi-Sun, Oh, Soo Joo, Lee, Jae Guk, Kim, Jun, Lee, Jae-Kwan, Cha, Dae-Hyun, Kim, Joon-Tae, Kim, Kang-Ho, Choi, Jay Chol, Choi, Eva, Lesén, Jonatan, Hedberg, Amarjeet, Tank, Edmond G, Fita, Ji Eun, Song, Ji Sung, Lee, Juneyoung, Lee, Hee-Joon, Bae
Publikováno v:
Journal of Korean Medical Science. 37
This study aimed to present the prognosis after minor acute ischemic stroke (AIS) or transient ischemic attack (TIA), using a definition of subsequent stroke in accordance with recent clinical trials. In total, 9,506 patients with minor AIS (National
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0318b5996c77dcfc5ff96cfbe17587
https://doi.org/10.3346/jkms.2022.37.e254
https://doi.org/10.3346/jkms.2022.37.e254
Autor:
Harriet E O Cant, Bryony E. Langford, Tao Haskins-Coulter, Lucy A. Eddowes, Molly O'Connor, Marc Evans, Christopher Edmonds, Amarjeet Tank
Publikováno v:
Diabetes, Obesity and Metabolism. 22:39-50
Aims To identify and synthesize phase 3 and phase 4 randomized controlled trials (RCTs) of sodium-glucose co-transporter (SGLT) inhibitors and metformin as adjuncts to insulin in type 1 diabetes (T1DM) using network meta-analysis (NMA). Materials and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2cdac5c1eceb2345396da648c7f089d
https://doi.org/10.1111/dom.13863
https://doi.org/10.1111/dom.13863
Autor:
Phil McEwan, Christopher Edmonds, Amarjeet Tank, H Bennett, Jason Gordon, Lee Beresford-Hulme
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 22(5)
AIMS To demonstrate the relationships between hypoglycaemia, body mass index (BMI) and quality of life, and to examine the impact of dapagliflozin on patient-reported treatment satisfaction in patients with type 1 diabetes mellitus (T1DM), using data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06ed0b8511c4d7caf95f7df7a5bb5415
https://pubmed.ncbi.nlm.nih.gov/31970881
https://pubmed.ncbi.nlm.nih.gov/31970881
Autor:
Tao Haskins-Coulter, Amarjeet Tank, Lucy A. Eddowes, Bryony E. Langford, Marc Evans, Christopher Edmonds, ME O'Connor, Heo Cant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66f0bed352ca04d7e60991d4f2987356
https://doi.org/10.1111/dom.13863/v2/response1
https://doi.org/10.1111/dom.13863/v2/response1
Autor:
Amarjeet Tank, Philip Christopher McEwan, Christopher Edmonds, Jason Gordon, Lee Beresford-Hulme, Hayley Bennett
Publikováno v:
Diabetes. 68
Insulin-treatment in type 1 diabetes mellitus (T1DM) is associated with elevated risk of hypoglycaemia and weight gain, which may act as a barrier to achieving optimal glycaemic control. For patients inadequately controlled by insulin alone, adjunct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b895decc60a7086df7ddcec333816661
https://doi.org/10.2337/db19-2356-pub
https://doi.org/10.2337/db19-2356-pub
Autor:
Harriet E O Cant, Mary-Ellen O'connor, Tao Haskins-Coulter, Lucy A. Eddowes, Amarjeet Tank, Christopher Edmonds, Bryony E. Langford, Marc Evans
Publikováno v:
Diabetes. 68
T1DM is characterized by deficient insulin production, requiring multiple daily insulin doses. However, glycemic control is often suboptimal, and insulin-associated weight gain and hypoglycemia are concerns. Therefore, adjunctive therapy may be benef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f85caebbeaa447fd16a76661bc5b2d6
https://doi.org/10.2337/db19-1233-p
https://doi.org/10.2337/db19-1233-p